Trends in Neurosciences
ReviewPET studies and motor complications in Parkinson's disease
References (80)
- et al.
Repeated l-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat
Neurosci. Res. Commun.
(1993) Changes in brain dopamine-receptors in MPTP parkinsonian monkeys following l-dopa treatment
Brain Res.
(1993)Continuous dopamine-receptor stimulation in early Parkinson's disease
Trends Neurosci.
(2000)Pathophysiology of the basal ganglia in Parkinson's disease
Trends Neurosci.
(2000)Effects of unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia
Eur. J. Pharmacol.
(1992)l-dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
Mol. Brain Res.
(1995)Functional implications of K-opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease
Brain Res.
(1995)On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
Exp. Neurol.
(1994)Primate models of movement disorders of basal ganglia origin
Trends Neurosci.
(1990)Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: Correlations with the three main symptoms
J. Neurol. Sci.
(1996)
Subtraction autoradiography of opiate receptor subtypes in human brain
Brain Res.
Localisation of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopamine system: lesion studies
Brain Res.
Striatal opiate receptors: Pre- and postsynaptic localisation
Life Sci.
Alterations in brain opiate receptors in Parkinson's disease
Brain Res.
Preproenkephalin and preprotachykinin messenger-RNA expression in normal human basal ganglia and in Parkinson's disease
Neuroscience
Focal cortical release of endogenous opioids during reading-induced seizures
Lancet
Levodopa-induced dyskinesia: review, observations, and speculations
Neurology
The response to levodopa in Parkinson's disease: imposing pharmacological law and order
Ann. Neurol.
Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
Science
Pathogenesis of dyskinesias in Parkinson's disease
Ann. Neurol.
Nigrostriatal damage is required for induction of dyskinesias by l-dopa in squirrel monkeys
Clin. Neuropharrnacol.
Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic l-dopa administration
Br. J. Pharmacol.
Characterisation of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides
J. Neural Transm.
Unilateral MPTP-induced parkinsonism in monkeys — a quantitative autoradiographic study of dopamine-D1 and dopamine-D2 receptors and reuptake sites
Neurochirurgie
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
J. Neurol. Neurosurg. Psychiatry
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up
J. Neurol. Neurosurg. Psychiatry
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications
Dyskinesia in Parkinson's disease: A 5-year study of ropinirole versus levodopa
New Engl. J. Med.
Differential effect of selective D-1 and D-2-dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
J. Pharmacol. Exp. Ther.
In vivo and in vitro studies of the dopamine system in movement disorders
Cerebrovasc. Brain Metab. Rev.
The comparative distribution of enkephalin, dynorphin, and substance P in the human globus pallidus and basal forebrain
Neuroscience
Striatal inhomogeneities and basal ganglia function
Mov. Disord.
Levodopa replacement therapy alters enzyme activities in striaturn and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
Brain Res.
Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys
Can. J. Neurol. Sci.
Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
Drugs and Aging
Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine
Ann. Neurol.
Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate
J. Neurochem.
Cerebral uptake and utilisation of therapeutic [β-11C]-l-DOPA in Parkinson's disease measured by positron emission tomography
Human striatal l-dopa decarboxylase activity estimated in vivo using 6-[18F]fluorodopa and positron emission tomography: error analysis and application to normal subjects
J. Cereb. Blood Flow Metab.
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy
Ann. Neural.
Cited by (28)
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys
2014, NeuropharmacologyCitation Excerpt :There is no clear consensus in the PD literature concerning relation between changes in LID and D1 receptors. D1 receptors were reported to be similar in PD patients whether treated or not with l-DOPA (Shinotoh et al., 1993) or decreased with long-term l-DOPA as measured by positron emission tomography (PET) (Brooks, 2000). In primates, striatal D1 receptor specific binding was reported to remain unchanged or increased after MPTP lesion (Alexander et al., 1993; Calon et al., 1995; Gagnon et al., 1990, 1995; Goulet et al., 2000; Guigoni et al., 2005).
Imaging movement-related activity in medicated Parkin-associated and sporadic Parkinson's disease
2010, Parkinsonism and Related DisordersCitation Excerpt :The pathophysiology underlying this treatment-related complication is still not fully understood, but converging evidence points towards a pathologically raised volatility of synaptic striatal dopamine levels [20]. Levodopa-induced dyskinesias are associated with higher peaks of pulsatile dopamine transmission in the striatum [21] which seems to be positively correlated with disease duration [22]. Increased levels of regional activity in premotor and dorsal prefrontal cortices, as described here and in a study measuring regional blood flow during levodopa-related dyskinesias [23] can be regarded as a plausible downstream effect of increasingly overstimulated striato-frontal projections.
SPECT and PET in atypical parkinsonism
2010, PET ClinicsCitation Excerpt :This finding has provided both a rationale for symptomatic therapy as well as a target for imaging agents. There have been at least 3 different presynaptic dopaminergic targets that are used successfully to interrogate the dopamine system, with several radioligands for each: the dopamine transporter (123I-FP-CIT [DaTSCAN] and many others),14 the vesicular transporter (11C-VMAT2, 18F-AV-133),15 and dopamine metabolism (18F-dopa) (Fig. 1).16,17 Although each of these targets represents a different aspect of presynaptic dopamine function, there exists now several decades' worth of research and clinical application in assessing dopamine system changes with these targets to differentially diagnose, monitor, and screen patients with movement disorders.
Intermittent Dopaminergic Stimulation causes Behavioral Sensitization in the Addicted Brain and Parkinsonism
2009, International Review of NeurobiologyCorticobasal degeneration: clinical aspects
2008, Handbook of Clinical NeurologyCitation Excerpt :The most specific feature was temporal atrophy, observed in CBD but not in PSP or CJD (Josephs et al., 2004a). Functional imaging, using PET and SPECT, shows a global reduction in cerebral blood flow/metabolism, with prefrontal, premotor, sensorimotor, parietal and superior temporal regions being particularly affected (Sawle et al., 1991; Brooks, 2000; Juh et al., 2005; Kreisler et al., 2005). The combination of cortical and subcortical features is often considered to be one of the most characteristic traits of CBD (Riley and Lang, 2000).
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement
2006, Parkinsonism and Related Disorders